Search results for Samalizumab
Samalizumab Biosimilar – Anti-CD200 mAb – Research Grade, ProteoGenix, PX-TA1250
Description of Samalizumab Biosimilar - Anti-CD200 mAb - Research Grade General information on Anti-CD200[Homo sapiens] (Samalizumab) Monoclonal Antibody Samalizumab has beeninvestigated for the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
Host
Reactivity
Applications
Conjugation
Samalizumab, Abbexa, abx831205
Samalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD200, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Research Grade Samalizumab (HW741016), abinScience, HW741016
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.